Nonetheless, our data show that the main clinical correlations were associated with SSTR1 and SSTR2 expression in GBM, suggesting also a potential prognostic-value of these receptors in GBM, which might be a common cellular/molecular-signature across various tumour-types that also have proposed a potential prognostic value of these receptors (e.g., colon cancer [59] and prostate cancer [60] for SSTR1, and rectal neuroendocrine-tumours [61], meningioma [62, 63], and nasopharyngeal carcinoma [64] for SSTR2). The gene discussed is SSTR2; the disease is prostate cancer.